Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

Blood - 9 Jun 2022

Perl Alexander E, Larson Richard A, Podoltsev Nikolai A, Strickland Stephen, Wang Eunice S, Atallah Ehab, Schiller Gary J, Martinelli Giovanni, Neubauer Andreas, Sierra Jorge, Montesinos Pau, Récher Christian, Yoon Sung-Soo, Hosono Naoko, Onozawa Masahiro, Chiba Shigeru, Kim Hee-Je, Hasabou Nahla, Lu Qiaoyang, Tiu Ramon, Levis Mark J

Abstract excerpt

The phase 3 ADMIRAL (NCT02421939; Study ID: 2215-CL-0301) trial showed superior overall survival in patients with relapsed/refractory FLT3-mutation-positive acute myeloid leukemia (AML) randomized 2:1 to receive the oral FMS-like tyrosine kinase 3 inhibitor gilteritinib vs those randomized to receive salvage chemotherapy (SC). Here we provide a follow-up of the ADMIRAL trial 2 years after the primary analysis to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Pyrazines

Share to Recurrence

Source

Open in PubMed Open full text

Identifiers

PMID: 35081255
DOI: 10.1182/blood.2021011583
PMCID: PMC9197557

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.PMID 35081255Read ↗

Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.Semantic proximity Read ↗

Outcomes of patients with R/R FLT3mut+ AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation.Semantic proximity Read ↗

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.Semantic proximity Read ↗

Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.Semantic proximity Read ↗

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.Semantic proximity Read ↗

Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutationSemantic proximity Read ↗

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 Mutated AML PatientsSemantic proximity Read ↗

FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation.Semantic proximity Read ↗

Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.Semantic proximity Read ↗

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.Semantic proximity Read ↗

Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.Semantic proximity Read ↗

Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.